E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10020161 |
E.1.2 | Term | HIV infection |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine whether a strategy of switching to PI monotherapy is as good as continuing triple drug therapy (the standard of care) in terms of the proportion of patients who maintain all possible drug treatment options after at least 3 years of follow-up.
|
|
E.2.2 | Secondary objectives of the trial |
To compare the two treatment strategies for : • Serious drug or disease-related complications • Adverse events • Virological rebound • CD4+ count change • Health-related Quality of life change • Neurocognitive function change • Cardiovascular risk change • Health care costs
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
INCLUSION CRITERIA 1. Documented HIV infection on ELISA and confirmatory test.
2. Male or female patients, aged 18 years or more.
3. Receiving combination ART for at least 24 weeks with a regimen comprising 2 NRTIs and either an NNRTI or a PI (boosted or un-boosted).
4. No change in ART drugs in the 12 weeks prior to screening.
5. Plasma VL <50 copies/ml at screening and for at least 24 weeks prior to screening (must have at least 1 documented result <50 copies/ml at more than 24 weeks prior to screening, and at least 1 documented result <50 copies/ml taken within 24 weeks prior to screening). A patient who has had one VL “blip” to <200 copies/ml in the 24 weeks prior to screening may be included, provided that the 2 VL tests that immediately preceded the blip and all the VL tests(of which there must be at least 1 prior to screening) that immediately followed the blip all gave results <50 copies/ml.
6. CD4+ count >100 cells/mm3 at screening. (This criterion is included because immune reconstitution is a priority in patients with very low CD4+ counts, and there is currently insufficient data to assess whether PI monotherapy will lead to equivalent rates of CD4+ recovery as standard-of-care treatment.)
7. Willing to continue unchanged or to modify, antiretroviral therapy, in accordance with the randomised assignment.
8. Likely to be resident in the UK for the full duration of the trial and willing to comply with trial visit schedule throughout the follow-up period.
9.Willing to provide written informed consent.
|
|
E.4 | Principal exclusion criteria |
EXCLUSION CRITERIA 1. Known major protease resistance mutation(s) documented on prior resistance testing if performed (prior resistance testing is not mandatory for trial participation).
2. Previous change in ART drug regimen for reasons of unsatisfactory virological response (patients who have changed regimen for prevention or managemnt of toxicity or to improve regimen convenience are permitted to enter the trial).
3. Previous allergic reaction to a PI.
4. Patient currently using or likely to require use of concomitant medication with known interaction with PI s including rifampicin, amiodarone, flecainide, bupropion, clozapine, ergotamine, mexilitine, midazolam, pethidine, pimozide, quinidine, sertindole, sildenafil, voriconazole, zolpidem, St John’s Wort.
5. Patient requiring treatment with radiotherapy, cytotoxic chemotherapy, or is anticipated to need these during the trial period.
6. Treatment for acute opportunistic infection within 3 months prior to trial screening.
7. Pregnant or trying to become pregnant at the time of trial entry.
8. History of active substance abuse or psychiatric illness that, in the opinion of the investigator, would preclude compliance with the protocol, dosing schedule or assessments.
9. History of HIV encephalopathy with current deficit >1 in any domain of the Neuropsychiatric AIDS Rating Scale.
10. Past or current history of cardiovascular disease, or 10 year absolute coronary heart disease risk of >30%, or risk of >20% if the patient has diabetes or a family history of premature ischaemic heart disease or stroke(based on the Framingham equation and assessed using the Joint British Societies cardiovascular risk prediction charts).
11. History of insulin-dependent diabetes mellitus.
12. Patient currently receiving interferon therapy for Hepatitis C virus infection or planning to start treatment for Hepatitis C at the time of study entry.
13. Co-infection with hepatitis B, defined as Hepatitis BsAg positive at screening or at any time since HIV diagnosis, unless the patient has had a documented Hepatitis B DNA measurement of less than 1000 copies/ml taken whilst off Hepatitis B active drug. (This criterion is included to avoid the risk of a flare of Hepatitis B with NRTI withdrawal.)
14. Any other active clinically significant condition, or findings during screening medical history or examination or abnormality on screening laboratory blood tests that would, in the opinion of the investigator, compromise the patient’s safety or outcome in the trial.
15. Fasting plasma glucose > 7.0mmol/L at trial screening.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Loss of future drug options: Defined as the first occurrence of intermediate to high level resistance to any one or more of the standard antiretroviral drugs (limited to licensed drugs in contemporary use) to which the patient’s virus was considered to be sensitive at trial entry (i.e. excluding drug resistance that was known to be present on previous resistance testing).
|
|
E.5.2 | Secondary end point(s) |
(i) Serious drug or disease-related complication. Defined as the first occurrence of one of the following in any individual patient:
o Death from any cause o Serious AIDS-defining illness (see diagnostic criteria, protocol appendix 8) o Serious non-AIDS defining illness (see diagnostic criteria, protocol appendix 9) -Acute myocardial infarction -Coronary artery disease requiring invasive procedures -Cirrhosis -Acute liver failure -End-stage renal disaese -Stroke -Clinical acute pancreatitis -Severe lactic acidaemia -Severe facial lipoatrophy -Severe peripheral neuropathy -Non-AIDS malignancy
(ii) Adverse events. Defined as the total number of Grade III and IV adverse events.
(iii) Virological rebound. Defined in two ways using the “Time to loss of virologic response” (TLOVR) algorithm :
o Two consecutive tests, taken at least 4 weeks apart, with VL more than 50 copies/ml (the first test must also be confirmed by re-testing the same blood sample). Patients who have virological rebound in the PI monotherapy arm, but re-suppress VL to <50 copies/ml with re-introduction of NRTIs, will not count as failures; OR
o As above, with at least one of the samples giving a VL result more than 400 copies/ml.
(iv) CD4+ count change. Defined as change from baseline in absolute CD4+ count.
(v) Health-related Quality of Life change. Defined as change from baseline in the mental and physical health summary scores.
(vi) Neurocognitive function change. Defined as change from baseline in the neurocognitive function summary score.
(vii) Cardiovascular risk change. Defined as change from baseline in the risk of cardiovascular disease calculated from the Framingham equation.
(viii) Health care costs. Defined as the total cost of health care resources utilised per patient year.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 44 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the main part of the PIVOT trial will be LVLS. However, as part of this substantial amendment the trial will be extended for a further 5 years to collect annual routine data. No further visits will be required. This extended phase of the trial will end at the last data collection point in Q1 2019. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 11 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 1 |
E.8.9.2 | In all countries concerned by the trial years | 11 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 1 |